Abstract
We used a purified bispecific antibody (Ab) against CD3 and an ovarian carcinoma (OVCA) antigen to ask whether the binding of a monovalent ligand to CD3 can induce triggering of T cells. In the presence of OVCA cells, this Ab bridges the CD3 complex to the target cell and triggers proliferation and cytotoxicity in T cells. In the absence of target cells, however, this monovalent Ab, even when bound to T cells at high levels, fails to induce any increase in cytosolic Ca2+, nor does it induce responsiveness to IL-2 or modulation of the CD3 complex. Because it is inert when bound monovalently, this hybrid Ab can be used to arm in vitro CTL clones, which then retain the capacity to kill the specific tumor for up to 2 d.
Full Text
The Full Text of this article is available as a PDF (375.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cobbold S. P., Waldmann H. Therapeutic potential of monovalent monoclonal antibodies. 1984 Mar 29-Apr 4Nature. 308(5958):460–462. doi: 10.1038/308460a0. [DOI] [PubMed] [Google Scholar]
- Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987 Jan;17(1):105–111. doi: 10.1002/eji.1830170118. [DOI] [PubMed] [Google Scholar]
- Milstein C., Cuello A. C. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983 Oct 6;305(5934):537–540. doi: 10.1038/305537a0. [DOI] [PubMed] [Google Scholar]
- Oettgen H. C., Terhorst C., Cantley L. C., Rosoff P. M. Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell. 1985 Mar;40(3):583–590. doi: 10.1016/0092-8674(85)90206-5. [DOI] [PubMed] [Google Scholar]
- Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul 25;316(6026):354–356. doi: 10.1038/316354a0. [DOI] [PubMed] [Google Scholar]
- Perez P., Hoffman R. W., Titus J. A., Segal D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med. 1986 Jan 1;163(1):166–178. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reinherz E. L., Meuer S., Fitzgerald K. A., Hussey R. E., Levine H., Schlossman S. F. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell. 1982 Oct;30(3):735–743. doi: 10.1016/0092-8674(82)90278-1. [DOI] [PubMed] [Google Scholar]
- Roosnek E. E., Van Lier R. A., Aarden L. A. Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur J Immunol. 1987 Oct;17(10):1507–1510. doi: 10.1002/eji.1830171019. [DOI] [PubMed] [Google Scholar]
- Roosnek E., Demotz S., Corradin G., Lanzavecchia A. Kinetics of MHC-antigen complex formation on antigen-presenting cells. J Immunol. 1988 Jun 15;140(12):4079–4082. [PubMed] [Google Scholar]
- Staerz U. D., Kanagawa O., Bevan M. J. Hybrid antibodies can target sites for attack by T cells. Nature. 1985 Apr 18;314(6012):628–631. doi: 10.1038/314628a0. [DOI] [PubMed] [Google Scholar]
- Tax W. J., Willems H. W., Reekers P. P., Capel P. J., Koene R. A. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 1983 Aug 4;304(5925):445–447. doi: 10.1038/304445a0. [DOI] [PubMed] [Google Scholar]